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PREAMBLE
This document has been developed as a Clinical Expert
Consensus Document (CECD), combining the resources of
the American College of Cardiology Foundation (ACCF)
and the European Society of Cardiology (ESC). It is
intended to provide a perspective on the current state of
management of patients with hypertrophic cardiomyopathy.
Clinical Expert Consensus Documents are intended to
inform practitioners, payers, and other interested parties of
the opinion of the ACCF and the ESC concerning evolving
areas of clinical practice and/or technologies that are widely
available or new to the practice community. Topics chosen
for coverage by expert consensus documents are so designed
because the evidence base, the experience with technology,
and/or the clinical practice are not considered sufficiently
well developed to be evaluated by the formal American
College of Cardiology/American Heart Association (ACC/
AHA) Practice Guidelines process. Often the topic is the
subject of considerable ongoing investigation. Thus, the
reader should view the CECD as the best attempt of the
ACC and the ESC to inform and guide clinical practice in
areas where rigorous evidence may not yet be available or the
evidence to date is not widely accepted. When feasible,
CECDs include indications or contraindications. Some
topics covered by CECDs will be addressed subsequently by
the ACC/AHA Practice Guidelines Committee.
The Task Force on Clinical Expert Consensus Docu-
ments makes every effort to avoid any actual or potential
conflicts of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest to inform the writing effort. These statements are
reviewed by the parent task force, reported orally to all
members of the writing panel at the first meeting, and
updated as changes occur.
Robert A. Vogel, MD, FACC
Chair, ACCF Task Force on Clinical Expert
Consensus Documents
Werner W. Klein, MD, FACC, FESC
Chair, ESC Committee for Practice Guidelines
INTRODUCTION
Organization of committee and evidence review. The
Writing Committee consisted of acknowledged experts in
hypertrophic cardiomyopathy (HCM) representing the
American College of Cardiology Foundation and the Eu-
ropean Society of Cardiology. Both the academic and
private practice sectors were represented. The document was
reviewed by 2 official reviewers nominated by the ACCF, 3
official reviewers nominated by the ESC, 12 members of the
ACCF Clinical Electrophysiology Committee, and 4 addi-
tional content reviewers nominated by the Writing Com-
mittee. The document was approved for publication by the
ACCF Board of Trustees in August 2003 and the Board of
ESC in July 2003. This document will be considered current
until the Task Force on Clinical Expert Consensus Docu-
ments revises or withdraws it from distribution. In addition
to the references cited as part of this document, a compre-
hensive bibliography including relevant, supplementary ref-
erences is available on the ACCF and ESC websites.
Purpose of this Expert Consensus Document. Hypertro-
phic cardiomyopathy is a complex and relatively common
genetic cardiac disorder (about 1:500 in the general adult
population) (1) that has been the subject of intense scrutiny
and investigation for over 40 years (2–15). Hypertrophic
cardiomyopathy affects men and women equally and occurs
in many races and countries, although it appears to be
under-diagnosed in women, minorities, and under-served
populations (16–20).
Hypertrophic cardiomyopathy is a particularly common
cause of sudden cardiac death (SCD) in young people
(including trained athletes) (21–29) and may cause death
and disability in patients of all ages, although it is also
frequently compatible with normal longevity (30–35). Be-
cause of its heterogeneous clinical course and expression
(7,36–42), HCM frequently presents uncertainty and rep-
resents a management dilemma to cardiovascular specialists
and other practitioners, particularly those infrequently en-
gaged in the evaluation of patients with this disease.
Furthermore, with the recent introduction of novel treat-
ment strategies targeting subgroups of patients with HCM
(7,43–49), controversy is predictable, and difficult questions
periodically arise. Consequently, it is now particularly timely
to clarify and place into perspective those clinical issues
relevant to the rapidly evolving management for HCM.
GENERAL CONSIDERATIONS AND PERSPECTIVES
This clinical scientific statement represents the consensus of
a panel of experts appointed by the ACC and ESC. The
writing group is comprised of cardiovascular specialists and
molecular biologists, each having extensive experience with
HCM. The panel focused largely on the management of
this complex disease and derived prudent, practical, and
contemporary treatment strategies for the many subgroups
of patients comprising the broad HCM disease spectrum.
Because of the relatively low prevalence of HCM in general
cardiologic practice (50), its diverse presentation, and mech-
anisms of death and disability and skewed patterns of
patient referral (7,11,13,36–38,42,51–59), the level of evi-
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dence governing management decisions for drugs or devices
has often been derived from non-randomized and retrospec-
tive investigations. Large-scale controlled and randomized
study designs, such as those that have provided important
answers regarding the management of coronary artery dis-
ease (CAD) and congestive heart failure (60–62), have
generally not been available in HCM as a result of these
factors. Therefore, treatment strategies have necessarily
evolved based on available data that have frequently been
observational in design, sometimes obtained in relatively
small patient groups, or derived from the accumulated
clinical experience of individual investigators, and reason-
able inferences drawn from other cardiac diseases. Conse-
quently, the construction of strict clinical algorithms de-
signed to assess prognosis and dictate treatment decisions
for all patients has been challenging and has not yet
achieved general agreement. In some clinical situations,
management decisions and strategies unavoidably must be
individualized to the particular patient.
Understanding of the molecular basis, clinical course, and
treatment of HCM has increased substantially in the last
decade. In particular, there has been a growing awareness of
the clinical and molecular heterogeneity characteristic of
this disorder and the many patient subgroups that inevitably
influence considerations for treatment. Some of these man-
agement strategies are novel and evolving, and this docu-
ment cannot, in all instances, convey definitive assessments
of their role in the treatment armamentarium. Also, for
some uncommon subsets within the broad disease spectrum,
there are little data currently available to definitively guide
therapy. With these considerations in mind, the panel has
aspired to create a document that is not only current and
pertinent but also has the potential to remain relevant for
many years.
NOMENCLATURE,
DEFINITIONS, AND CLINICAL DIAGNOSIS
The clinical diagnosis of HCM is established most easily
and reliably with two-dimensional echocardiography by
demonstrating left ventricular hypertrophy (LVH) (typically
asymmetric in distribution, and showing virtually any diffuse
or segmental pattern of left ventricular [LV] wall thicken-
ing) (36). Left ventricular wall thickening is associated with
a nondilated and hyperdynamic chamber (often with systolic
cavity obliteration) in the absence of another cardiac or
systemic disease (e.g., hypertension or aortic stenosis) capa-
ble of producing the magnitude of hypertrophy evident, and
independent of whether or not LV outflow obstruction is
present (1,5,7,36). Although the usual clinical diagnostic
criteria for HCM is a maximal LV wall thickness greater
than or equal to 15 mm, genotype-phenotype correlations
have shown that virtually any wall thickness (including those
within normal range) are compatible with the presence of a
HCM mutant gene (6,17,19,63–65). Mildly increased LV
wall thicknesses of 13 to 14 mm potentially due to HCM
should be distinguished from certain extreme expressions of
the physiologically-based athlete’s heart (66–68). The ad-
vent of contemporary magnetic resonance imaging that
provides high-resolution tomographic images of the entire
LV may represent an additional diagnostic modality (69)
particularly in the presence of technically suboptimal echo-
cardiographic studies or when segmental hypertrophy is
confined to unusual locations within the LV wall.
Since the modern description by Teare in 1958 (12),
HCM has been known by a confusing array of names that
largely reflect its clinical heterogeneity, relatively uncom-
mon occurrence in cardiologic practice, and the skewed
experience of early investigators. This problem in nomen-
clature has been an obstacle to general recognition of the
disease within the medical and non-medical community.
Hypertrophic cardiomyopathy (or HCM) is now widely
accepted as the preferred term (7) because it describes the
overall disease spectrum without introducing misleading
inferences that LV outflow tract obstruction is an invariable
feature of the disease, such as is the case with hypertrophic
obstructive cardiomyopathy (70), muscular subaortic steno-
sis (71), or idiopathic hypertrophic subaortic stenosis (72).
Indeed, most patients with HCM do not demonstrate
outflow obstruction under resting (basal) conditions, al-
though many may develop dynamic subaortic gradients of
varying magnitude with provocative maneuvers or agents
(7,13,41,72–77). Of note, even though the absence of
obstruction (at rest) is common, both in patients with and
without symptoms, most treatment modalities have targeted
those symptomatic HCM patients with outflow obstruction
(41,43–49,78–108).
OBSTRUCTION TO LV OUTFLOW
It is of clinical importance to distinguish between the
obstructive or nonobstructive forms of HCM, based on the
presence or absence of a LV outflow gradient under resting
and/or provocable conditions (5,7,11,13,41,109,110). In-
deed, in most patients, management strategies have tradi-
tionally been tailored to the hemodynamic state. Outflow
gradients are responsible for a loud apical systolic ejection
murmur associated with a constellation of unique clinical
signs (14,72,111), hypertrophy of the basal portion of
ventricular septum and small outflow tract, and an enlarged
and elongated mitral valve in many patients (39,112–114).
Obstruction may either be subaortic (13,71,72) or mid-
cavity (13,115) in location. Subaortic obstruction is caused
by systolic anterior motion (SAM) of the mitral valve
leaflets and mid-systolic contact with the ventricular septum
(13,71,113,116–119). This mechanical impedance to out-
flow occurs in the presence of high velocity ejection in
which a variable proportion of the forward blood flow may
be ejected early in systole (120,121). Systolic anterior
motion is probably attributable to a drag effect (117,122) or
possibly a Venturi phenomenon (13,118) and is responsible
not only for subaortic obstruction, but also the concomitant
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mitral regurgitation (usually mild-to-moderate in degree)
due to incomplete leaflet apposition, which is typically
directed posteriorly into the left atrium (111,123). When
the mitral regurgitation jet is directed centrally or anteriorly
into the left atrium, or if multiple jets are present, indepen-
dent abnormalities intrinsic to the mitral valve should be
suspected (e.g., myxomatous degeneration, mitral leaflet
fibrosis, or anomalous papillary muscle insertion)
(13,91,115,124). Occasionally (perhaps in 5% of cases),
gradients and impeded outflow are caused predominately by
muscular apposition in the mid-cavity region—usually in
the absence of mitral-septal contact—involving anomalous
direct insertion of anterolateral papillary muscle into the
anterior mitral leaflet, or excessive mid-ventricular or pap-
illary muscle hypertrophy and malalignment (13,91,115).
Although it has previously been subject to periodic
controversy (72,120,125,126), there is now widespread rec-
ognition that the subaortic gradient (30 mm Hg or more)
and associated elevations in intra-cavity LV pressure reflect
true mechanical impedance to outflow and are of patho-
physiologic and prognostic importance to patients with
HCM (127,128). Indeed, outflow obstruction is a strong,
independent predictor of disease progression to HCM-
related death (relative risk vs. nonobstructed patients, 2.0),
to severe symptoms of New York Heart Association
(NYHA) class III or IV, and to death due specifically to
heart failure and stroke (relative risk vs. nonobstructed
patients, 4.4) (127). However, the likelihood of severe
symptoms and death from outflow tract obstruction was not
greater when the gradient was increased in magnitude above
the threshold of 30 mm Hg (127).
Disease consequences related to chronic outflow gradi-
ents are likely to be mediated by the resultant increase in LV
wall stress, myocardial ischemia and eventually cell death
and replacement fibrosis (7,127,129). Therefore, the pres-
ence of LV outflow obstruction justifies intervention to
reduce or abolish significant subaortic gradients in severely
symptomatic patients who are refractory to maximum med-
ical management (11,14,41,127).
Obstruction in HCM is characteristically dynamic (i.e.,
not fixed): the magnitude (or even presence) of an outflow
gradient may be spontaneously labile and vary considerably
with a number of physiologic alterations as diverse as a
heavy meal or ingestion of a small amount of alcohol
(72,73,109). Different gradient cut-offs have been proposed
for segregating individual patients into hemodynamic sub-
groups, but rigorous partitioning into such hemodynamic
categories according to gradient can be difficult because of
the unpredictable dynamic changes that may occur in
individual patients (72,73).
Nevertheless, it is reasonable to divide the overall HCM
disease spectrum into hemodynamic subgroups, based on
the representative peak instantaneous gradient as assessed
with continuous wave Doppler: 1) obstructive gradient
under basal (resting) conditions equal to or greater than 30
mm Hg (2.7 m/s by Doppler), 2) latent (provocable)
obstructive—gradient less than 30 mm Hg under basal
conditions and equal to or greater than 30 mm Hg with
provocation, and 3) nonobstructive—less than 30 mm Hg
under both basal and (provocable) conditions. By current
clinical convention, LV outflow gradients are routinely
measured noninvasively with continuous wave Doppler
echocardiography, generally obviating the need for serial
cardiac catheterizations in this disease (except when athero-
sclerotic CAD or other associated anomalies such as intrin-
sic valvular disease are suspected).
It is important to underscore that a variety of interven-
tions have been traditionally employed to elicit latent
(inducible) gradients in the echocardiography, cardiac cath-
eterization, and exercise laboratories (i.e., amyl nitrite inha-
lation, Valsalva maneuver, post-premature ventricular con-
traction response, isoproterenol or dobutamine infusion,
standing posture, and physiologic exercise) (3,72,73), how-
ever, rigorous standardization for these maneuvers has been
lacking, and many have come to be regarded as non-
physiologic. To define latent gradients during and/or im-
mediately following exercise for the purpose of major
management decisions, treadmill or bicycle exercise testing
in association with Doppler echocardiography is probably
the most physiologic and preferred provocative maneuver,
given that HCM-related symptoms are typically elicited
with exertion. Intravenous administration of dobutamine is
undesirable (130,131), as discussed under the section on
alcohol septal ablation.
GENETICS AND MOLECULAR DIAGNOSIS
Hypertrophic cardiomyopathy is inherited as a Mendelian
autosomal dominant trait and is caused by mutations in any
one of 10 genes, each encoding protein components of the
cardiac sarcomere composed of thick or thin filaments with
contractile, structural, or regulatory functions (6,9,17–
19,64,65,132–139). It is possible to regard the diverse
clinical spectrum as a single, unified disease entity and
primary disorder of the sarcomere (18,63). Three of the
HCM-causing mutant genes predominate in frequency—
i.e., beta-myosin heavy chain (the first identified), myosin-
binding protein C and cardiac troponin-T probably com-
prise more than one-half of the genotyped patients to date.
Seven other genes each account for fewer cases: regulatory
and essential myosin light chains, titin, alpha-tropomyosin,
alpha-actin, cardiac troponin-I, and alpha-myosin heavy
chain. This genetic diversity is compounded by intragenic
heterogeneity, with about 200 mutations now identified (see
http://genetics.med.harvard.edu/seidman/cg3), most of
which are missense, with a single amino acid residue
substituted with another (63). Indeed, molecular defects
responsible for HCM are usually different in unrelated
individuals, and many other mutations in previously iden-
tified genes (and even in additional genes, each probably
accounting for a small proportion of familial HCM) un-
doubtedly remain to be identified.
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Phenotypic expression of HCM (i.e., LVH) is the prod-
uct not only of the causal mutation, but also of modifier
genes and environmental factors (140,141). The magnitude
of effect that modifier genes have on morphologic expres-
sion has not yet been systematically explored, but it can be
inferred from the phenotypic variability of affected individ-
uals in the same family carrying identical disease-causing
mutations. As a result of the complexity of the molecular
biology of hypertrophy, a large number of genes may
influence the expression of the phenotype. There is also
increasing recognition of the role of genetics in the genesis
of electrophysiological abnormalities associated with LVH.
For example, an increased risk for atrial fibrillation (AF) in
HCM has been identified with a beta-myosin heavy chain
Arg663 His mutation (136).
Missense mutations in the gene encoding the gamma-2-
regulatory subunit of the AMP-activated protein kinase
(PRKAG2), a regulator of cellular energy homeostasis, have
been reported to cause familial LVH associated with ven-
tricular pre-excitation (134,142). Absence of classical histo-
pathology such as myocyte disarray, a distinct molecular
cause for LVH (in part, reflecting glycogen accumulation in
myocytes), and progressive conduction system disease and
heart block distinguish PRKAG2 from sarcomere protein
gene mutations typical of HCM (142). Indeed, this syn-
drome is probably most appropriately regarded as a meta-
bolic storage disease distinct from true HCM. Therefore, it
may not be optimal to base management and clinical risk
assessment of patients with cardiac hypertrophy and Wolff-
Parkinson-White on the data derived from patients with
HCM. Also, thickening of the LV wall resembling HCM
occurs in children (and some adults) with other disease
states—e.g., Noonan’s syndrome, mitochondrial myopa-
thies, Friedreich’s ataxia, metabolic disorders, Anderson-
Fabry disease (X-linked deficiency of the lysosomal enzyme
alpha-galactosidase) (143,144), LV non-compaction (145),
and cardiac amyloidosis (110).
Molecular genetic studies over the past decade have
underscored and provided important insights into the pro-
found clinical and genetic heterogeneity of HCM, including
the power to achieve preclinical diagnosis of individuals who
are affected by a mutant gene but who show no evidence of
the disease phenotype on a two-dimensional echocardio-
gram (or electrocardiogram [ECG]) (6,17,57,64,65,
146,147). Indeed, HCM may be even more common in the
general population than the cited prevalence of 1:500 (based
on recognition of the established phenotype by echocardi-
ography) (1) because of incomplete, time-dependent, variable
expression of the disease phenotype and because many affected
individuals have not been clinically recognized and are not
represented in general cardiologic practice, where the disease is
relatively uncommon (50). In the clinical assessment of indi-
vidual pedigrees, it is obligatory for the proband to be informed
of the familial nature and autosomal dominant transmission of
HCM.
Not all individuals harboring a genetic defect will express
the clinical features of HCM (e.g., LVH on echocardio-
gram, abnormal ECG pattern or disease-related symptoms)
at all times during life, and 12-lead ECG abnormalities or
evidence of diastolic dysfunction assessed by Doppler tissue
imaging may even precede the appearance of the phenotype
on echocardiogram especially in the young (148–151).
Indeed, clinical and molecular genetic studies have demon-
strated that there is in fact no minimum LV wall thickness
required to be consistent with the presence of an HCM-
causing mutant gene (17,65,146–148,152). For example, it
is common for children less than 13 years old to be affected
“silent” mutation carriers without evidence of LVH on an
echocardiogram. Most commonly, substantial LV remodel-
ing with the spontaneous appearance of LVH occurs asso-
ciated with accelerated body growth and maturation during
the adolescent years and with morphologic expression usu-
ally completed at the time physical maturity is achieved
(about 17 to 18 years) (150,152,153).
Furthermore, novel diagnostic criteria for HCM have
recently emerged, based on genotype-phenotype studies
showing that incomplete penetrance and disease expression
with absence of (or minimal) LVH may occur in adult
individuals (most commonly due to cardiac myosin-binding
protein-C or troponin-T mutations) (17,19,65,135,149,
151). In both cross-sectional (17) and serial echocardio-
graphic studies (65), mutations in myosin-binding protein
C gene have demonstrated age-related penetrance and
late-onset of the phenotype in which delayed and de novo
appearance of LVH on echocardiogram occurs in mid-life
and even later. Therefore, the traditional tenet that held that
a normal echocardiogram (and ECG) obtained after full
growth has been achieved defined a genetically unaffected
relative has been revised. Such late-onset adult morphologic
conversions dictate that it is no longer possible, based solely
on a normal echocardiogram and ECG, to issue definitive
reassurance to asymptomatic family members at maturity (or
even in middle-age) that they are free of a disease-causing
mutant HCM gene.
Clinical screening of first-degree relatives and other
family members should be encouraged. Therefore, when a
DNA-based diagnosis is not feasible, the recommended
clinical strategies for screening family members employ
history and physical examination, 12-lead ECG, and two-
dimensional echocardiography at annual evaluations during
adolescence (12 to18 years of age). Due to the possibility of
delayed adult-onset LVH, it is reasonable and prudent to
recommend that adult relatives with normal echocardio-
grams at or beyond age 18 have subsequent clinical studies
performed about every five years. Screening in relatives younger
than age 12 is not usually pursued systematically unless the
child has a high-risk family history or is involved in particularly
intense competitive sports programs. Affected patients identi-
fied through family screening (or otherwise) are conventionally
evaluated on approximately a 12- to 18-month basis, as
described under Risk Stratification and Sudden Cardiac Death
heading.
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Laboratory DNA analysis for mutant genes is the most
definitive method for establishing the diagnosis of HCM.
At present, however, there are several obstacles to the
translation of genetic research into practical clinical appli-
cations and routine clinical strategy. These include the
substantial genetic heterogeneity, the low frequency with
which each causal mutation occurs in the general HCM
population, and the important methodologic difficulties
associated with identifying a single disease-causing muta-
tion among 10 different genes in view of the complex,
time-consuming, and expensive laboratory techniques in-
volved. Mutation analysis is presently confined to a few
research-oriented laboratories. The current development of
better methodologies for automated, direct DNA sequenc-
ing and indirect approaches for sequence profiling now
provides sensitive techniques that can accurately define the
molecular cause for HCM in a single proband, without
involving family members or complex linkage analysis in
large pedigrees. However, the large number and size of the
genes that may need to be examined in each proband
continue to limit the efficiency of a gene-based diagnosis.
However, once a mutation is defined in a proband, an
accurate definition of genetic status in all family members is
both efficient and inexpensive.
Although there is interest in the application of gene
therapy to a variety of inheritable human conditions, at this
time the clinical utilization of this technology in HCM is
extremely problematic. Hypertrophic cardiomyopathy is
transmitted as an autosomal dominant trait, and affected
persons possess one mutated and one normal allele. Because
most mutations in this disease cause substitution of a single
amino acid within the encoded protein, gene therapy would
theoretically have the daunting task of selectively targeting
and inactivating the mutated gene, the encoded protein, or
both. Furthermore, selection of patients for gene therapy
would be particularly complex given that some forms of the
disease are compatible with normal longevity and absence of
symptoms. Also, such therapeutic interventions would pre-
sumably be applicable only to a small patient subset consisting
of very young affected members from high-risk families iden-
tified prior to the development of LVH. Spontaneous animal
models of HCM (154), or model organisms including mice
and rabbits, may foster the development of pharmacologic
therapies that reduce disease manifestations, including hyper-
trophy and interstitial (matrix) fibrosis (155–158).
GENERAL CONSIDERATIONS FOR
NATURAL HISTORY AND CLINICAL COURSE
Hypertrophic cardiomyopathy is a unique cardiovascular
disease with the potential for clinical presentation during
any phase of life from infancy to old age (day one to over 90
years). The clinical course is typically variable, and patients
may remain stable over long periods of time with up to 25%
of a HCM cohort achieving normal longevity (75 years of
age or older) (7,30,31,34,159). However, the course of many
patients may be punctuated by adverse clinical events, largely
related to sudden, unexpected death, embolic stroke, and the
consequences of heart failure (5,7,29,30,38). Hypertrophic
cardiomyopathy is also a rare cause of severe heart failure in
infants and very young children, and presentation in this age
group itself constitutes an unfavorable prognostic sign (53,58).
In general, adverse clinical course proceeds along one or
more of several of the following pathways, which ultimately
dictate treatment strategies (Figs. 1 and 2) (5,7,11,14,26): 1)
high risk for premature sudden and unexpected death; 2)
progressive symptoms largely of exertional dyspnea, chest pain
(either typical of angina or atypical in nature), and impaired
consciousness, including syncope, near-syncope or presyncope
(i.e., dizziness/lightheadedness), in the presence of preserved
LV systolic function; 3) progression to advanced congestive
heart failure (the “end-stage phase”) with LV remodeling and
systolic dysfunction (37,160); and 4) complications attributable
to AF, including embolic stroke (38,161–163).
However, full appreciation of the clinical implications of
HCM (and its treatment strategies) requires an awareness of
the unique patterns of patient referral and selection biases
that have had an important impact on our perceptions of
this disease (5,7,11,59,164). Perhaps to a far greater extent
than other cardiovascular diseases, much of the published
clinical data assembled over four decades have emanated
largely from a few selected tertiary centers in North America
and Europe, disproportionately comprised of patients re-
ferred because of their high-risk status or severe symptoms
requiring highly specialized care (such as surgery) (59,164).
On the other hand, clinically stable, asymptomatic, or
elderly patients were often under-represented.
Over-dependence on frequently cited, ominous mortality
rates of 3% to 6% per year for HCM-related premature
death from tertiary centers may have led to an exaggeration
of the overall risk and impact of this disease on patients and,
thereby, contributed to a misguided perception that HCM
is invariably an unfavorable disorder with inevitable, adverse
consequences frequently requiring major therapeutic inter-
vention (7,59,165). However, more recent reports from
non-tertiary centers with fewer selected, regional, and
community-based cohorts not subject to tertiary center
referral bias are probably more representative of the overall
disease state, citing annual mortality rates in a much lower
range of about 1%, with the survival of patients not
dissimilar to that of the general adult U.S. population
(7,30,31). Nevertheless, of note, there are subgroups of
patients within the broad HCM spectrum with annual
mortality rates far exceeding 1% and conform to the rates of
up to 6% per year previously attributed to the overall disease
(7,11,41,165,166).
Hypertrophic cardiomyopathy attributable to sarcomere
protein mutations also occurs in the elderly (139) and
should be distinguished from non-genetic hypertensive
heart disease or age-related changes in persons of advanced
age. The determinants of extended survival in some patients
with HCM are largely unresolved. It is possible that benign
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genetic substrates may convey favorable prognosis and
normal life expectancy. However, at present, genotype data
are available for only a limited number of elderly patients,
with mutations in the cardiac myosin-binding protein C
gene being most common (139). Older patients with HCM
characteristically show relatively mild degrees of LVH and
may not experience severe symptoms. Some even have large
resting subaortic gradients that are often caused by the
SAM-septal contact associated with normal-sized mitral
leaflets greatly displaced anteriorly, seemingly by calcium
accumulation posteriorly in the mitral annulus, within a
particularly small LV outflow tract (167). Definitive clinical
diagnosis of HCM in older patients with LVH and systemic
hypertension is often difficult to resolve, particularly when
LV wall thickness is less than 20 mm and SAM is absent. In
the absence of genotyping, marked LVH disproportionate
to the level of blood pressure elevation, unusual patterns of
LVH unique to HCM (36), or an obstruction to LV outflow
at rest represents presumptive evidence for HCM (127).
Not uncommonly, HCM coexists with other cardiac
conditions such as systemic hypertension and/or CAD. In
such patients, the management of HCM should be consid-
ered independent of any co-morbidity, and each of the
disease entities should be treated on its own merit. For
example, specific concerns that may arise include avoidance
of angiotensin-converting enzyme (ACE) inhibitors to con-
trol hypertension in the presence of HCM-related resting or
provocable LV outflow tract obstruction and failure to
exclude the diagnosis of CAD in those HCM patients with
angina pectoris.
In summary, it is probably most appropriate to regard HCM
as a complex disease capable of producing important clinical
consequences and premature death in some patients, while
many other patients reach normal longevity and life expectancy
with mild or no disability and without major therapeutic
interventions. Many individuals affected by HCM may not
require treatment for most or all of their natural lives, and they
therefore deserve reassurance with regard to their prognosis.
SYMPTOMS AND
PHARMACOLOGICAL MANAGEMENT STRATEGIES
A fundamental goal of treatment in HCM is the alleviation
of symptoms related to heart failure (Fig. 1). Pharmacolog-
Figure 1. Clinical presentation and treatment strategies for patient subgroups within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM).
See text for details. AF  atrial fibrillation; DDDdual-chamber; ICD  implantable cardioverter-defibrillator; SD  sudden death. Adapted with
permission (11). *No specific treatment or intervention indicated, except under exceptional circumstances.
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ical therapy has traditionally been the initial therapeutic
approach for relieving disabling symptoms of exertional
dyspnea (with or without associated chest pain) and improv-
ing exercise capacity for more than 35 years, since the
introduction of beta-blockers in the mid-1960s (3,10,14,
168–179). Also, drugs are often the sole therapeutic option
available to the many patients without obstruction to LV
outflow, under resting or provocable conditions, who con-
stitute a substantial proportion of the HCM population.
Indeed, it is the convention to empirically initiate pharmaco-
logic therapy when symptoms of exercise intolerance intervene,
although there have been few randomized trials to compare the
effect of drugs in HCM (5,7,11,179) (Fig. 1).
Exertional dyspnea and disability (often associated chest
pain), dizziness, presyncope and syncope usually occur in
the presence of preserved systolic function and a nondilated
LV (5,7,11,14,180). Symptoms appear to be caused in large
measure by diastolic dysfunction with impaired filling due to
abnormal relaxation and increased chamber stiffness, leading
in turn to elevated left atrial and LV end-diastolic pressures
(with reduced stroke volume and cardiac output) (181–188),
pulmonary congestion, and impaired exercise performance
with reduced oxygen consumption at peak exercise (189).
The pathophysiology of such symptoms, due to this form
of diastolic heart failure, may also be intertwined with other
important pathophysiologic mechanisms such as myocardial
ischemia (190–201), outflow obstruction associated with
mitral regurgitation (13,127), and AF (163). Indeed, many
patients may experience symptoms largely from diastolic
dysfunction or myocardial ischemia in the absence of out-
flow obstruction (or severe hypertrophy). Other patients
(i.e., those with LV outflow obstruction) are more disabled
by elevated LV pressures and concomitant mitral regurgi-
tation than by diastolic dysfunction, as is evidenced by the
often dramatic symptomatic benefit derived from major
therapeutic interventions that reduce or obliterate outflow
gradient (most frequently myectomy or alcohol ablation)
(7,13–15,49,81,83–88,90–95,102–106,202).
Chest pain in the absence of atherosclerotic CAD may be
typical of angina pectoris or atypical in character. Most
chest discomfort is probably due by bursts of myocardial
ischemia, evidenced by the findings of scars at autopsy
(51,195,199,203), fixed or reversible myocardial perfusion
defects and the suggestion of scarring by magnetic reso-
nance imaging (129), net lactate release during atrial pacing,
and impaired coronary vasodilator capacity (190,192,193,
198,201,204). Myocardial ischemia is probably a conse-
quence of abnormal microvasculature, consisting of intra-
mural coronary arterioles with thickened walls (from medial
hypertrophy) and narrowed lumen (195–201), and/or a
mismatch between the greatly increased LV mass and
coronary flow. Because typical anginal chest pain may be
part of the HCM symptom-complex, associated atheroscle-
rotic CAD (which may complicate clinical course) is often
overlooked in these patients. Therefore, coronary arteriog-
raphy is indicated in patients with HCM and persistent
Figure 2. The principal pathways of disease progression in hypertrophic cardiomyopathy (HCM). Widths of the respective arrows approximate the
frequency with which the pathway occurs in HCM populations. AF  atrial fibrillation.
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angina who are over 40 years of age or who have risk factors
for CAD, or when CAD is judged possible prior to any
invasive treatment for HCM such as septal myectomy (or
alcohol septal ablation).
Beta-adrenergic blocking agents. Beta-blockers are neg-
ative inotropic drugs that have traditionally been adminis-
tered to HCM patients with or without obstruction, usually
relying on the patient’s own subjective and historical per-
ception of benefit (11,14,168,169,172,179). However, judg-
ments regarding treatment strategies in HCM with beta-
blockers are often difficult, taking into account the frequent
day-to-day variability in magnitude of symptoms. Treadmill
or bicycle exercise—with or without measurement of peak
oxygen consumption (189)—have proved helpful in target-
ing patients for therapy or determining when changes in
dosage or drugs are appropriate. If limiting symptoms
progress, drug dosage may be increased within the accepted
therapeutic range. Patient responses to drugs are highly
variable in terms of magnitude and duration of benefit, and
the selection of medications has not achieved widespread
standardization and has been dependent, in part, on the
experiences of individual practitioners, investigators, and
centers.
Propranolol was the first drug used in the medical
management of HCM, and long-acting preparations of
propranolol or agents such as atenolol, metoprolol, or
nadolol have been employed more recently. There are many
reports of subjective symptomatic improvement and en-
hanced exercise capacity in a dose range of up to 480 mg per
day for propranolol (2 mg/kg in children), both in patients
with and without outflow obstruction. Although some
investigators have administered massive doses of proprano-
lol (up to 1,000 mg per day), claiming symptomatic benefit
and long-term survival without major side effects (172), this
is not generally accepted practice. However, even moderate
doses of beta-blockers may affect growth in young children
or impair school performance, or trigger depression in
children and adolescents, and should be closely monitored
in such patients.
Substantial experience suggests that standard dosages of
these drugs can mitigate disabling symptoms and limit the
latent outflow gradient provoked during exercise when
sympathetic tone is high and heart failure symptoms occur.
However, there is little evidence that beta-blocking agents
consistently reduce outflow obstruction under resting con-
ditions. Consequently, beta-blockers are a preferred drug
treatment strategy for symptomatic patients with outflow
gradients present only with exertion.
The beneficial effects of beta-blockers on symptoms of
exertional dyspnea and exercise intolerance appear to be
attributable largely to a decrease in the heart rate with a
consequent prolongation of diastole and relaxation and an
increase in passive ventricular filling. These agents lessen
LV contractility and myocardial oxygen demand and possi-
bly reduce microvascular myocardial ischemia. Potential side
effects include fatigue, impotence, sleep disturbances, and
chronotropic incompetence.
Verapamil. In 1979, the calcium antagonist verapamil was
introduced as another negative inotropic agent for the
treatment of HCM (170), and has been widely used
empirically in both the nonobstructive and obstructive
forms, with a reported benefit for many patients, including
those with a component of chest pain (176,205,206).
Verapamil in doses up to 480 mg per day (usually in a
sustained release preparation) has favorable effects on symp-
toms, probably by virtue of improving ventricular relaxation
and filling as well as relieving myocardial ischemia and
decreasing LV contractility (181,182,206). However, aside
from the mild side effect of constipation, verapamil may also
occasionally harbor a potential for clinically important
adverse consequences and has been reported to cause death
in a few HCM patients with severe disabling symptoms
(orthopnea and paroxysmal nocturnal dyspnea) and mark-
edly elevated pulmonary arterial pressure in combination
with marked outflow obstruction (14). Adverse hemody-
namic effects of verapamil are presumably the result of the
vasodilating properties predominating over negative inotro-
pic effects, resulting in augmented outflow obstruction,
pulmonary edema, and cardiogenic shock. Because of these
concerns, caution should be exercised in administering
verapamil to patients with resting outflow obstruction and
severe limiting symptoms. Some investigators discourage
the use of calcium antagonists in the management of
obstructive HCM and instead favor disopyramide (often
with a beta-blocker) for such patients with severe symptoms
(14,173). Verapamil is not indicated in infants due to the
risk for sudden death that has been reported with intrave-
nous administration. Dosages of oral verapamil have not
been established for infants and preadolescent children.
Most clinicians favor using beta-blockers over verapamil
for the initial medical treatment of exertional dyspnea,
although it does not appear to be of crucial importance
which drug is administered first. It has been common
practice, however, to administer verapamil to those patients
who do not experience a benefit from beta-blockers or who
have a history of asthma. Improvement with verapamil may
be due to the primary actions of the drug, and in some
instances, partially attributable to withdrawal of beta-
blockers and the abolition of side effects that evolved
insidiously over time. At present, there is no evidence that
combined medical therapy with administration of beta-
blockers and verapamil is more advantageous than the use of
either drug alone.
Disopyramide. The negative inotropic and type I-A anti-
arrhythmic agent disopyramide was introduced into the
treatment regimen for patients with obstructive HCM in
1982. There are reports of disopyramide producing symp-
tomatic benefit (at 300 to 600 mg per day with a dose-
response effect) in severely limited patients with resting
obstruction, because of a decrease in SAM, outflow obstruc-
tion, and mitral regurgitant volume (168,171,173,174,177).
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Anti-cholinergic side effects such as dry mouth and eyes,
constipation, indigestion, and difficulty in micturition may
be reduced by long-acting preparations through which
cardioactive benefits are more sustained. Because disopyr-
amide may cause accelerated atrioventricular (A-V) nodal
conduction and thus increase ventricular rate during AF,
supplemental therapy with beta-blockers in low doses to
achieve normal resting heart rate has been advised.
Although disopyramide incorporates antiarrhythmic
properties, there is little evidence that proarrhythmic effects
have intervened in HCM patients. Nevertheless, this issue
remains of some concern in a disease associated with an
arrhythmogenic LV substrate; prolongation of the QT
interval should be monitored while administering the drug.
Furthermore, disopyramide administration may be delete-
rious in nonobstructive HCM by decreasing cardiac output,
causing most investigators to limit its use to patients with
outflow obstruction who have not responded to beta-
blockers or verapamil.
At present, the information regarding drugs such as
sotalol and other calcium antagonists (such as diltiazem) is
insufficient to recommend their use in HCM. Diuretic
agents may be added to the cardioactive drug regimen
prudently—preferably in the absence of marked outflow
obstruction. Because many patients have diastolic dysfunc-
tion and require relatively high filling pressures to achieve
adequate ventricular filling, it may be advisable to adminis-
ter diuretics cautiously. Nifedipine, because of its particu-
larly potent vasodilating properties, may be deleterious,
particularly for patients with outflow obstruction. Com-
bined therapy with disopyramide and amiodarone (or diso-
pyramide and sotalol), or quinidine and verapamil (or
quinidine and procainamide), should also be avoided due to
concern over proarrhythmia; also, administration of nitro-
glycerine, ACE inhibitors or digitalis are generally contra-
indicated or discouraged in the presence of resting or
provocable outflow obstruction. In patients with severe
heart failure refractory to other medications, caution is
advised in administrating amiodarone in a high dosage
(greater than or equal to 400 mg per day). In patients with
erectile dysfunction, phosphodiesterase inhibitors should be
used with the awareness that a mild afterload reducing effect
may be deleterious in patients with resting or provocable
obstruction.
Drugs in end-stage phase. A small but important sub-
group of patients with nonobstructive HCM develops
systolic ventricular dysfunction and severe heart failure,
usually associated with LV remodeling demonstrable as wall
thinning and chamber enlargement. This particular evolu-
tion of HCM occurs in only about 5% of patients and has
been variously known as the “end-stage,” “burnt-out,” or
“dilated” phase (7,37,160). Drug treatment strategies in
such patients with systolic failure differ substantially from
those approaches in HCM patients with typical LVH,
nondilated chambers, and preserved systolic function (i.e.,
involving conversion to after load-reducing agents such as
ACE inhibitors or angiotensin-II receptor blockers or
diuretics, digitalis, beta-blockers or spironolactone) (Fig. 1).
There is no evidence, however, that beta-blockers prevent or
convey a benefit to congestive heart failure and ventricular
systolic dysfunction of the “end-of-stage” (by contrast with
the experience in dilated cardiomyopathy and CAD). Ulti-
mately, patients with end-stage heart failure may become
candidates for heart transplantation, and they represent the
primary subgroup within the broad disease spectrum of
HCM for when this treatment option is considered (207)
(Fig. 1).
Asymptomatic patients. Data from largely unselected co-
horts and genotyping studies in families suggest that most
HCM patients, including many who are not even aware of
their disease, probably have no symptoms or only mild
symptoms (5–7,17–19,30,50,55,59,64,65,164). While most
of the asymptomatic patients do not require treatment,
some represent therapeutic dilemmas because of their
youthful age and the consideration for prophylactic therapy
to prevent SCD or disease progression (21,27,127,208,209).
Prophylactic drug therapy in asymptomatic (or mildly
symptomatic) patients to prevent or delay development of
symptoms and improve prognosis has been the subject of
debate for many years, but it remains on an entirely empiric
basis without controlled data to either support or contradict
its potential efficacy (11). This issue is unresolved due to the
relatively small patient populations previously available for
study, as well as the infrequency with which adverse end
points occur prematurely in this disease. Additionally, there
is a growing awareness that an important proportion of
HCM patients achieve normal life expectancy (30 –
32,34,55). In general, treatments to delay or prevent pro-
gression of the disease due to heart failure-related symptoms
are most appropriately directed toward relieving LV outflow
tract obstruction and controlling or abolishing AF through
pharmacologic or intervention-based strategies. Indeed,
treatments targeted at aborting the disease progression are
now confined to those patients judged to be at high-risk for
SCD (as discussed under Risk Stratification and Sudden
Cardiac Death). The efficacy of empiric, prophylactic drug
treatment with beta-blockers, verapamil or disopyramide for
delaying the onset of symptoms and favorably altering the
clinical course or outcome in asymptomatic young patients
with particularly marked LV outflow tract gradients (about
75 to 100 mm Hg or more) is unresolved.
Infective endocarditis prophylaxis. In HCM there is a
small risk for bacterial endocarditis, which appears largely
confined to those patients with LV outflow tract obstruction
under resting conditions or with intrinsic mitral valve
disease (210). The site of the valvular vegetation is usually
the thickened anterior mitral leaflet, although cases have
been reported with lesions on the outflow tract endocardial
contact plaque (at the point of mitral-septal contact) or on
the aortic valve (210,211). Therefore, the AHA recommen-
dation (212) should be applied to HCM patients with
evidence of outflow obstruction under resting or exercise
1696 Maron and McKenna et al. JACC Vol. 42, No. 9, 2003
ACC/ESC Expert Consensus Document on Hypertrophic Cardiomyopathy November 5, 2003:1687–713
conditions at the time of dental or selected surgical proce-
dures that create a risk for blood-borne bacteremia.
Pregnancy. There is no evidence that patients with HCM
are generally at increased risk during pregnancy and deliv-
ery. Absolute maternal mortality is very low (although
possibly higher in patients with HCM than in the general
population) and appears to be confined principally to
women with high-risk clinical profiles (213). Such patients
should be afforded highly specialized preventive obstetrical
care during pregnancy. Otherwise, most pregnant HCM
patients undergo normal vaginal delivery without the neces-
sity for cesarean section.
TREATMENT OPTIONS
FOR DRUG-REFRACTORY PATIENTS
In some patients, medical therapy ultimately proves insuf-
ficient to control symptoms, and the quality of life becomes
unacceptable to the patient. At this point in the clinical
course, after administration of maximum drug treatment,
the subsequent therapeutic strategies are dictated largely by
whether LV outflow obstruction is present (Fig. 1).
Surgery. Patients in a small but important subgroup com-
prising only about 5% of all HCM patients in non-referral
settings (but up to 30% in tertiary referral populations), are
generally regarded as candidates for surgery. These patients
have particularly marked outflow gradients (peak instanta-
neous usually greater than or equal to 50 mm Hg), as
measured with continuous wave Doppler echocardiography
either under resting/basal conditions and/or with provoca-
tion preferably utilizing physiologic exercise. In addition,
these patients have severe limiting symptoms, usually of
exertional dyspnea and chest pain that are regarded in adults
as NYHA functional classes III and IV, refractory to
maximum medical therapy (7,8,11,14,41,90,92,102,103).
Over the past 40 years, based on the experience of a number
of centers throughout the world, the ventricular septal
myectomy operation (also known as the Morrow procedure)
(8) has become established as a proven approach for ame-
lioration of outflow obstruction and the standard therapeu-
tic option, and the gold standard, for both adults and
children with obstructive HCM and severe drug-refractory
symptoms (7,11,14,15,41,70,78,81,84,85,90 –95,102–
106,214). The myectomy operation should be confined to
centers experienced in this procedure.
Myectomy is performed through an aortotomy and in-
volves the resection of a carefully defined relatively small
amount of muscle from the proximal septum (about 5 to
10 g), extending from near the base of the aortic valve to
beyond the distal margins of mitral leaflets (about 3 to 4
cm), thereby enlarging the LV outflow tract (215) and, as a
consequence in the vast majority of patients, abolishing any
significant mechanical impedance to ejection and mitral
valve SAM immediately normalizing LV systolic pressures,
abolishing mitral regurgitation, and ultimately, reducing LV
end-diastolic pressures. Such an abrupt relief of the gradient
with surgery (in contrast to slower reduction with alcohol
septal ablation in many cases) is particularly advantageous in
patients with severe functional limitations.
Some surgeons have utilized a more extensive myectomy
procedure for obstructive HCM, with the septal resection
widened and extended far more distally than in the classic
Morrow procedure (i.e., 7 to 8 cm from the aortic valve to
below the level of papillary muscles) (70,91). In addition,
the anterolateral papillary muscle may be dissected partially
free from its attachment with the lateral LV free wall to
enhance papillary muscle mobility and reduce anterior
tethering of the mitral apparatus (91). Alternatively, mitral
valve replacement or repair has been employed in selected
patients judged to have severe mitral regurgitation due to
intrinsic abnormalities of the valve apparatus (such as
myxomatous mitral valve) (124).
Previously, some surgeons found it advantageous in
selected patients to perform mitral valve replacement
(216,217) when the basal anterior septum in the area of
resection is relatively thin (e.g., less than 18 mm) and
muscular resection was judged to present an unacceptable
risk of septal perforation or inadequate hemodynamic result
(93). However, currently, some surgical centers experienced
with myectomy do not advocate mitral valve replacement (in
the absence of intrinsic mitral valve disease), even in the
presence of a relatively thin ventricular septum; carefully
performed surgical septal reduction is the preferred method.
Mitral valvuloplasty (plication) in combination with my-
ectomy has been proposed for some patients with particu-
larly deformed or elongated mitral leaflets (84). Muscular
mid-cavity obstruction due to an anomalous papillary mus-
cle requires an extended distal myectomy (91) or alterna-
tively mitral valve replacement (115). Occasionally, patients,
usually children, may demonstrate an obstruction to right
ventricular outflow due to excessive muscular hypertrophy of
trabeculae or crista supraventricularis muscle (218); resec-
tion of the right ventricular outflow tract muscle, with or
without an outflow tract patch, has abolished the gradient.
Published reports of over 2,000 patients from North
American and European centers show remarkably consis-
tent results with the ventricular septal myectomy operation.
Isolated myectomy (without concomitant cardiac proce-
dures such as valve replacement or coronary artery bypass
grafting) is now performed with low operative mortality in
patients of all ages, including children, at those centers
having the most experience with this procedure (reported as
1% to 3%, and even less in the most recent cases)
(7,11,15,81,92–95,101–107). Surgical risk may be higher
among very elderly patients (particularly those with severe
disabling symptoms associated with pulmonary hyperten-
sion), patients with prior myectomy, or those undergoing
additional cardiac surgical procedures. Complications such
as complete heart block (requiring permanent pacemaker)
and iatrogenic ventricular septal perforation have become
uncommon (equal to or less than 1% to 2%), while partial or
complete left bundle-branch block is an inevitable conse-
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quence of the muscular resection and is not associated with
adverse sequelae (15,81,85,90–93,102–106). Intraoperative
guidance with echocardiography (transesophageal or with
the transducer applied directly to the right ventricular
surface) is standard at centers performing surgery for HCM
and is useful in assessing the site and extent of the proposed
myectomy, structural features of the mitral valve, and the
effect of muscular resection on SAM and mitral regurgita-
tion (93,123,219).
Septal myectomy is associated with persistent, long-
lasting improvement in disabling symptoms and exercise
capacity (i.e., increase by one or more NYHA classes and
demonstrable increase in peak oxygen consumption with
exercise) and decreased frequency of syncope five or more
years after surgery (7,11,13–15,81,90–95,102–106,220).
Symptomatic benefit following myectomy appears to be
largely the consequence of abolishing or substantially reduc-
ing the basal outflow gradient and mitral regurgitation, and
restoring normal LV systolic and end-diastolic pressures (in
more than 90% of patients), which may also favorably
influence LV diastolic filling and myocardial ischemia (204).
Because myectomy may result in a decrease in left atrial size
(221), the likelihood of AF occurring after surgery may be
mitigated (and sinus rhythm restored with greater ease),
especially in patients younger than 45 years.
Selected patients in whom severe refractory symptoms are
indisputably linked to marked outflow gradients elicited by
exercise (when resting obstruction is absent or mild) usually
also benefit from myectomy. Reacquisition of SAM and a
large resting LV outflow gradient is exceedingly uncommon
after successful myectomy in either adults or children, and
the need for reoperation to reduce recurrent outflow gradi-
ent is extremely uncommon at centers having the most
experience with the septal myectomy operation (15,81,95,
103,105).
By convention, surgery has not been recommended or
performed in asymptomatic or mildly symptomatic patients
with obstructive HCM for a number of reasons: 1) the effect
of surgery per se on longevity is unresolved, although several
surgical series have reported improved late survival after
myectomy compared with the clinical course of nonoperated
medically treated patients with severe symptoms; 2) opera-
tive mortality is now very low, but in some patients the risk
of surgery may exceed the ultimate risks from the disease; 3)
outflow obstruction is often compatible with normal lon-
gevity; and 4) there is little or no evidence that surgical relief
of outflow obstruction abolishes the risk for progression to
the end-stage phase, which is an independent disease
consequence.
Although definitive evidence is lacking, there is some
suggestion in retrospective non-randomized studies that
surgical relief of outflow obstruction in severely symptom-
atic patients may reduce long-term mortality and possibly
SCD (10,95,105). It should be emphasized that surgery is
not regarded as curative but is performed to achieve an
improved quality of life and functional (exercise) capacity.
One possible exception to this tenet may be young asymp-
tomatic or mildly symptomatic patients with particularly
marked outflow obstruction (e.g., 75 to 100 mm Hg or more
at rest). There is a paucity of data in this subset, but it is not
unreasonable to at least consider surgical intervention for
young patients, even if they are not severely symptomatic, in
the presence of particularly marked obstruction to LV
outflow.
ADDITIONAL APPROACHES TO RELIEVE
OUTFLOW OBSTRUCTION AND SYMPTOMS
Ventricular septal myectomy has generally been confined to
selected major centers having substantial experience with
this procedure. However, some patients may not have ready
access to such specialized surgical care because of geograph-
ical factors; or they may not be favorable operative candi-
dates, because of concomitant medical conditions—
particularly advanced age, prior cardiac surgery, or
insufficient personal motivation. Two techniques can be
considered as potential alternatives to surgery for selected
patients who otherwise meet the same clinical criteria as
candidates for surgery.
Dual-chamber pacing. Several groups had investigated the
effects of permanent dual-chamber pacing on severe outflow
obstruction and refractory symptoms within observational
and uncontrolled study designs (80,100,222). Data in these
studies were necessarily based on the subjective perception
of symptom level by patients over relatively short periods of
time. Such investigations reported dual-chamber pacing to
be associated with a substantial decrease in outflow gradient,
as well as amelioration of symptoms in most patients. These
observations inferred that a reduction of gradient with
pacing in turn consistently relieved symptoms. However,
other catheterization laboratory studies showed that a de-
crease in the outflow gradient produced by temporary A-V
sequential pacing could be associated with detrimental
effects on ventricular filling and cardiac output (97,223).
Subsequently, dual-chamber pacing in HCM was sub-
jected to scrutiny in three randomized, cross-over studies
(double-blind in two) in which patients received 2 to 3
months each of pacing and also back-up AAI mode (no
pacing) as a control, by activating and deactivating the
pacemaker accordingly (43,47,98,99). Two randomized,
cross-over, double-blind studies (one multicenter and one
from the Mayo Clinic) reported the effects of pacing in
HCM patients to be less favorable than the observational
data had suggested (43,98). For example, the average
decrease in outflow gradient with pacing, while statistically
significant, was nevertheless much more modest (about 25% to
40%) than reported in the uncontrolled studies and varied
substantially among individual patients. In one study, the
average subaortic gradient, even after nine months of pacing,
remained in the preoperative range (e.g., average 48 mm Hg).
In these controlled studies, subjective symptomatic im-
provement assessed by quality-of-life score was reported
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with similar frequency by patients both after periods of
pacing and after the same time period without pacing
(AAI-backup) (43,98). Objective measures of exercise ca-
pacity (e.g., treadmill exercise time and maximum oxygen
consumption) did not differ significantly during pacing and
without pacing. These observations demonstrate that sub-
jectively reported symptomatic benefit during pacing fre-
quently occurs without objective evidence of improved
exercise capacity and can be regarded in part as a placebo
effect (43,89,98). Furthermore, no correlation has been
demonstrated for gradient reduction between short- and
long-term pacing, suggesting that testing the gradient
response to short-term pacing in the catheterization labo-
ratory has limited practical clinical value in judging long-
term efficacy (43). However, the failure to achieve gradient
reduction with temporary pacing suggests that permanent
pacing is probably not indicated.
As part of its design, the randomized, cross-over, single-
blind European multicenter HCM pacing trial, PIC (Pac-
ing in Cardiomyopathy) (47,48,89,107), excluded from
chronic pacing those patients without significant gradient
reduction during temporary pacing. With data very similar
to the other two randomized studies (but also with a large
proportion of patients who elected to continue pacing based
on their own subjective assessment of treatment), the PIC
investigators concluded that pacemaker therapy was an
option for most severely symptomatic patients with obstruc-
tive HCM refractory to drug treatment. Nevertheless, taken
together the available data do not support dual-chamber
pacing as a primary treatment for most severely symptom-
atic patients with obstructive HCM. In a nonrandomized
study comparing pacing and the myectomy operation, he-
modynamic and symptomatic outcome proved to be supe-
rior with surgery (99).
Although it is not a primary treatment for the disease,
there is nevertheless evidence to support utilizing a trial of
dual-chamber pacing in selected patient subgroups that may
benefit in terms of gradient relief and improvement in
symptoms and exercise tolerance. For example, there may be
both subjective and objective symptomatic benefit with
pacing in some patients of advanced age (over 65 years) (43),
for whom alternatives to surgery are often desirable. Oth-
erwise, there are few predictive data upon which to specif-
ically target those patients who are most likely to potentially
benefit from pacing therapy; for example, there is little
relationship between the magnitude of gradient reduction
with chronic pacing and the symptomatic benefit ultimately
achieved. Pacing-induced LV remodeling with thinning of
the wall was claimed in one uncontrolled study (80) but
could not be confirmed in a randomized investigation (43).
Furthermore, there is no evidence that pacing reduces the
risk of SCD in HCM (43,80), alters or aborts underlying
progression of the disease state, or conveys favorable hemo-
dynamic or symptomatic benefit for patients with the
nonobstructive form (224).
Of potential advantage, pacing therapy permits more
aggressive drug treatment by obviating the concern for
drug-induced bradycardia (82). Some patients receiving an
implantable cardioverter defibrillator (ICD) for high-risk
status, in which obstruction to LV outflow is also present,
may benefit from use of the dual-chamber pacing compo-
nent of the ICD to effect a reduction in outflow gradient.
The ACC/AHA/NASPE 2002 guidelines have designated
pacing for severely symptomatic and medically refractory
HCM patients with LV outflow obstruction as a class IIB
indication (225).
However, it should be underscored that maintenance of
pacing therapy (directed toward alleviating obstruction and
symptoms) may be substantially more complex in HCM
than in other cardiac conditions; therefore, for optimal
results this procedure should be performed in centers highly
experienced in both pacemaker therapy and HCM. Produc-
ing and maintaining a reduction in gradient (and presum-
ably in symptoms) requires that pre-excitation of the right
ventricular apex and distal septum be established and that
complete ventricular capture—both at rest and during
exercise—without compromising ventricular filling and car-
diac output. Hence, ascertaining the optimal A-V interval
for dual-chamber pacing is a crucial element of pacing
management in HCM. Programming of the pacemaker
A-V interval to ensure complete ventricular capture may
require slowing of intrinsic A-V nodal conduction with a
beta-blocker or verapamil, or possibly ablation of the A-V
node in selected cases (thereby rendering the patient pace-
maker dependent), has been suggested. It is also understood
that no other treatment modality in HCM (including
surgery and alcohol septal ablation) has undergone such
rigorous randomized testing in order to validate its efficacy.
At present, there are no data concerning the role of
biventricular pacing in HCM patients with severe heart
disease.
Percutaneous alcohol septal ablation. A second alterna-
tive to surgery is the more recently developed alcohol septal
ablation technique (Table 1) (44–46,49,79,83,86–88,101,
226–234). First reported in 1995, this catheter interven-
tional treatment involves the introduction of absolute alco-
hol into a target septal perforator branch of the left anterior
descending coronary artery for the purpose of producing a
myocardial infarction within the proximal ventricular sep-
tum. Septal ablation mimics the hemodynamic conse-
quences of myectomy by reducing the basal septal thickness
and excursion (producing akinetic or hypokinetic septal
motion), enlarging the LV outflow tract and, thereby,
lessening the SAM of the mitral valve and mitral regurgi-
tation (44–46,49,88,227).
This technique utilizes conventional methods and tech-
nology currently available for atherosclerotic CAD. After
standard coronary arteriograms are performed, a coronary
balloon is placed into a proximal major septal perforator
artery with the aid of flexible coronary guide wires. A
temporary pacing catheter is positioned in the right ventric-
ular apex in the event that high-grade A-V block occurs.
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After the balloon is inflated, an arteriogram is performed
through the lumen to verify that the balloon is located in the
desired anatomic position and to ensure that leakage of
alcohol into the left anterior descending coronary artery or
coronary venous system does not occur.
Myocardial contrast echocardiography guidance (with
injection of echo contrast or radio-opaque medium) is
important in selecting the appropriate septal perforator
branch. This technique is useful for determining the precise
area of septum targeted for alcohol and infarction and
whether the selected septal perforator also perfuses other
distant and unwanted areas of LV or right ventricular
myocardium or papillary muscles (79,230). Some groups
prefer a pressure-angiographic and fluoroscopy-guided
technique (226,227,233). The targeted septal perforator and
area for infarction are identified by an immediate fall in
outflow gradient following balloon occlusion and/or con-
trast injection.
The amount of ethanol to be injected is estimated by the
angiographic visualization of septal anatomy and whether
contrast wash-out is slow or rapid (46,79,86,226,233).
Usually, about 1 to 3 cc (average 1.5 to 2 cc) of desiccated
ethanol (of at least 95% concentration) is slowly infused into
the septal perforator and septum via the balloon catheter,
inducing a myocardial infarction demonstrable by 400 to
2,500 units of creatinine phosphokinase release, equivalent
to an area of necrosis estimated to be 3% to 10% of the LV
mass (20% of the septum). However, centers performing a
large number of alcohol septal ablation procedures today are
using smaller amounts of ethanol, leading to less creatinine
phosphokinase release and smaller septal infarcts, and also
reducing the incidence of complete heart block (44,233).
Successful alcohol septal ablation may trigger a rapid
reduction in resting outflow gradient evident in the cathe-
terization laboratory. More frequently, a progressive de-
crease in the gradient occurs after 6 to 12 months, usually
achieving levels in a range equivalent to that with myec-
tomy, and resulting from remodeling of the septum without
significant impairment in global LV ejection (46,49,229–
234). This has been reported for patients with large resting
gradients at baseline as well as those with outflow obstruc-
tion present only under provocable conditions (234). Often
a biphasic response of the gradient is observed with alcohol
septal ablation in which an acute response with striking
reduction (probably due to stunning of the myocardium) is
followed by a rise to about 50% of its pre-procedure level the
next day, but within several months may reach greatly
reduced levels. Results of myectomy and alcohol ablation
compared at two institutions showed similar gradient re-
ductions with the two techniques (96). Another compara-
tive analysis from a single institution showed both surgery
and ablation to substantially reduce resting and provocable
gradients, but to a significantly greater degree with surgery
(101).
A number of other favorable structural and functional
effects following ablation have been reported (231), repre-
senting the expected consequences of reduced outflow
gradient, normalization of LV pressures, and reduced sys-
tolic overload. Echocardiographic analyses from two groups
have reported ablation to be associated with widespread
regression of LVH beyond the alcohol target area
(229,233), but the extent to which remodeling occurs with
time secondary to this procedure is unpredictable and not
fully understood. Also, there is concern that extensive wall
thinning could lead to arrhythmogenic susceptibility or even
the end-stage phase.
A large proportion of ablation patients from several
centers have been reported to demonstrate subjective im-
provement in limiting symptoms and in quality of life in
observational studies over relatively short-term follow-up
periods of 2 to 5 years. As with surgery, the decrease in
symptoms associated with ablation is often dramatic
(44,46,49,88,101,108,232,234). In addition, improved ex-
ercise performance has been shown objectively in terms of
total treadmill exercise time and peak oxygen consumption
in some studies (46,96,101,232). However, alcohol septal
ablation has yet to be subjected to the scrutiny of random-
ized or controlled studies or long-term follow-up. A recent
study found that both septal myectomy and ablation led to
improved exercise testing parameters, but surgery was supe-
rior in this regard (232).
The mortality and morbidity associated with alcohol
Table 1. Comparison of Septal Myectomy and Percutaneous Alcohol Septal Ablation*
Parameter Myectomy Ablation
Operative mortality 1% to 2% 1% to 2%
Gradient reduction (at rest) to less than 10 mm Hg to less than 25 mm Hg
Symptoms (subjective) decreased decreased
Symptoms (objective) decreased decreased
Effectiveness despite anatomic variability usually uncertain
Pacemaker (high grade A-V block) 1% to 2% 5% to 10%
Procedure frequency  15 to 20
Sudden death risk (long-term) very low uncertain
Available follow-up more than 40 years about 6 years
Intramyocardial scar absent present
*Data represents best estimates based on the assimilation of published data, and with emphasis placed on the most recent clinical
experience.
A-V  atrioventricular.
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ablation in experienced centers have proved to be relatively
low, although they are similar in surgical myectomy.
Procedure-related mortality has been reported to be from
1% to 4% but is probably reduced in the more recent cases.
Reports of permanent pacemaker implantation for induced
high-grade A-V block have ranged from 5% to as high as
30% (46,88,101,228), but this complication appears to be
decreasing substantially with the use of smaller amounts of
alcohol. In contrast to septal myectomy, which usually
produces left bundle branch block, alcohol ablation com-
monly results in right bundle branch block (45,46). It is also
possible for coronary artery dissection to occur, as well as
backward extravasation of alcohol, producing occlusion or
abrupt coronary no-flow (87) and a large anteroseptal
myocardial infarction.
Proper selection of patients for alcohol septal ablation
remains a crucial issue (228). Similar to patients recom-
mended for septal myectomy (5,7,8,11,13,41), all candidates
for alcohol septal ablation should have severe heart failure
symptoms (NYHA classes III or IV) refractory to all
medications utilized in HCM as well as a subaortic gradient
of 50 mm Hg or more measured with Doppler echocardi-
ography either under basal conditions and/or with physio-
logic provocative maneuvers during exercise (228). Caution
should be exercised so that in patients selected for alcohol
septal ablation, outflow gradients are documented to be due
to SAM and proximal mitral valve-septal contact (119),
exclusive of congenital abnormalities of the mitral apparatus
such as anomalous papillary muscle insertion into mitral
valve, which produces more distal muscular obstruction in
the mid-cavity (91,115).
Nevertheless, the number of alcohol ablations performed
world-wide now approaches an estimated 3,000 over only
about a six-year period, exceeding the number of surgical
myectomies performed over the 40 years since this operation
was introduced (228). In some instances, the frequency with
which myectomy surgery has been performed for obstructive
HCM has now been reduced by more than 90% (103,228)
due to the recent accelerated enthusiasm for ablation.
Disproportionality in the frequency with which alcohol
septal ablation is performed relative to myectomy (ablations
are estimated to be at least 15 to 20 times more common
than surgery at present) has raised concerns that there may
have been an insidious and unjustifiable lowering of the
symptom and gradient-level threshold in the selection of
patients for ablation, with less symptomatic (in NYHA class
II), less obstructed, and younger patients now undergoing
the procedure (228). This circumstance has evolved in part
because of the relative ease with which ablation can be
performed (compared to surgery), with substantially less
discomfort during a much shorter postoperative hospitaliza-
tion and recovery period in the absence of a sternotomy.
However, this fact does not justify less strict criteria for
alcohol septal ablation.
Another factor that has affected patient selection for
alcohol septal ablation is the practice of determining eligi-
bility based solely on a subaortic gradient provoked by
non-physiologic interventions such as dobutamine infusion
(rather than exercise, for example) (88,230). Dobutamine is
an inotropic and catecholamine-inducing drug that is a
powerful stimulant of subaortic gradients in normal hearts
or in cardiac diseases other than HCM (130,131,235) of
questionable physiologic and clinical significance (235), and
occasionally results in adverse consequences to patients with
obstruction; dependence on dobutamine to induce gradients
can expose some patients to septal ablation in the absence of
true impedance to LV outflow. Therefore, dobutamine is
generally not recommended for the purpose of provoking
outflow gradients in severely symptomatic HCM patients
who are regarded as possible candidates for major interven-
tions.
A predominate concern raised with respect to alcohol
septal ablation is the potential long-term risk for
arrhythmia-related cardiac events (including SCD) directly
attributable to the procedure. Unlike myectomy, alcohol
septal ablation potentially creates a permanent arrhythmo-
genic substrate in the form of a healed intramyocardial
septal scar that could increase the risk of lethal re-entrant
arrhythmias (226). This is particularly relevant because
many patients with HCM already possess an unstable
electrophysiologic substrate as part of their underlying
disease (2,208,236,237). However, since HCM patients are
at increased risk for SCD over particularly long periods,
possibly through much of their lifetimes, it will require
many years (and probably decades) to determine the likeli-
hood that risk for arrhythmia-related events and SCD is
increased as a consequence of the healed intramyocardial
scar produced by alcohol septal ablation. Indeed, this is
particularly relevant for young patients in whom even a
modest annual increase in the risk of SCD would have the
likelihood of shortening life considerably. Reports of the
non-inducibility of re-entrant ventricular tachyarrhythmia
in small numbers of patients in the short term after septal
ablation (46) do not appear sufficient at this juncture to
exclude the possibility of late-onset ventricular tachyar-
rhythmias and SCD over the long risk period characteristic
of HCM (26,208).
Therefore, at present, the impact of alcohol ablation on
the incidence of SCD is unresolved. Until more is known
regarding the natural history of patients undergoing alcohol
septal ablation and there is less uncertainty regarding the
consequences of the intramyocardial scar, particularly care-
ful selection of patients seems advisable and prudent (by
largely confining the procedure to older adults), particularly
when the option for surgical myectomy is feasible. There
would not appear to be a primary role for alcohol ablation in
children, and such procedures are not advised.
Due to morphologic heterogeneity, not all HCM patients
with obstruction are ideal candidates for septal ablation.
This therapy relies on the fixed anatomic distribution and
size of the septal perforator coronary arteries. Therefore, the
ablation technique cannot make adjustments for variability
1701JACC Vol. 42, No. 9, 2003 Maron and McKenna et al.
November 5, 2003:1687–713 ACC/ESC Expert Consensus Document on Hypertrophic Cardiomyopathy
in the distribution and size of these arterial vessels in
relation to the distribution of septal hypertrophy, or for
other complexities of LV outflow tract morphology such as
greatly elongated mitral leaflets and anomalous papillary
muscle. The direct operative approach provides greater
flexibility for relieving obstruction and also allows surgical
treatment for associated cardiac abnormalities such as pri-
mary valvular disease (e.g., myxomatous mitral valve pro-
lapse or aortic stenosis) (124), atherosclerotic CAD, or
segmental myocardial bridging of the left anterior descend-
ing coronary artery (238), as well as anomalies of the mitral
valve and apparatus. Also, relief of obstruction with surgery
is immediate (but is often delayed with alcohol septal
ablation), which may be crucial in some patients with
particularly severe symptoms of heart failure.
The “learning curve” for expertise with the alcohol septal
ablation technique is steep (due, in part, to the relatively
small number of eligible HCM patients), particularly re-
garding selection of the optimal septal perforator branch;
therefore, ablation should not be regarded as a routine
technique to be employed by any expert interventional
cardiologist. It is advisable that alcohol ablation (as well as
myectomy) be largely confined to centers having substantial
and specific experience with HCM and the procedure in
order to assure proper patient selection, the lowest possible
rates of morbidity and mortality, and the greatest likelihood
of achieving benefits.
While alcohol ablation represents an option available to
HCM patients and a selective alternative to surgery, it is
not at this time regarded as the standard and primary
therapeutic strategy for all severely symptomatic patients
refractory to maximal medical management with marked
obstruction to LV outflow (Table 1). Septal myectomy
remains the gold standard for this HCM patient subset
(7,11,14,41,232).
SUDDEN CARDIAC DEATH
Risk stratification. Since the modern description of HCM
by Teare in 1958 (12), sudden and unexpected death has
been recognized as the most devastating and often unpre-
dictable complication and the most frequent mode of
premature demise from this disorder. Sudden cardiac death
may occur as the initial disease presentation, most fre-
quently in asymptomatic or mildly symptomatic young
people (7,10,21–29,42,56,208,209,237–248). The high-risk
HCM patients constitute only a minority of the overall
disease population (5,7,11,21,22,27,249), and historically, a
major investigative focus has been the isolation of the small
but important subset of patients at high-risk among the
overall HCM spectrum. Since SCD can be the initial
manifestation of HCM (23,25–27,239), it often occurs
without reliable warning signs or symptoms, and often in
the early morning hours after awakening (24). Although
SCD is most frequent in adolescents and young adults less
than 30 to 35 years old, such risk also extends through
mid-life and beyond (26); the basis for this particular
predilection of SCD for the young is unresolved. Therefore,
achieving any particular age does not itself confer an
immunity to sudden HCM-related catastrophe. Sudden
cardiac death occurs most commonly during mild exertion
or sedentary activities (or during sleep), but it is not
infrequently triggered by vigorous physical exertion (23,25).
Indeed, HCM is the most common cause of cardiovascular-
related SCD in young people, including competitive ath-
letes (most commonly in basketball and football) (25).
The available data (largely from recorded arrhythmic
events that triggered appropriate defibrillator interventions)
suggest that complex ventricular tachyarrhythmias emanat-
ing from an electrically unstable myocardial substrate are the
most common mechanism by which SCD occurs in HCM
(2,208,209,236,237). Indeed, ventricular arrhythmias are an
important clinical feature in adults with HCM. On routine
ambulatory (Holter) 24-h ECG monitoring, 90% of adults
demonstrate ventricular arrhythmias, which are often fre-
quent or complex, including premature ventricular depolar-
izations (greater than or equal to 200 in 20% of patients),
ventricular couplets (in greater than 40%) or nonsustained
bursts of ventricular tachycardia (VT) (in 20% to 30%)
(250). Alternatively, it is possible that in some patients
supraventricular tachyarrhythmias could trigger ventricular
tachyarrhythmias or that bradyarrhythmias occur and re-
quire back-up pacing.
It has been suggested that life-threatening tachyarrhyth-
mias could be provoked in HCM by a number of variables
either secondary to environmental factors (e.g., intense
physical exertion) (23,25) or, alternatively, intrinsic to the
disease process. The latter may involve a vicious cycle of
increasing myocardial ischemia (190,192–198,238,251) and
diastolic (or systolic) dysfunction (37,181–188), possibly
impacted by outflow obstruction (13,127), systemic arterial
hypotension (29,252,253), or supraventricular tachyarrhyth-
mias (163,244,254) which lead to decreased stroke volume
and coronary perfusion.
Although the available data on the stratification of SCD
risk are substantial and a large measure of understanding has
been achieved, it is important to underscore that precise
identification of all individual high-risk patients by clinical
risk markers is not completely resolved. This issue remains
a challenge due largely to the heterogeneity of HCM disease
presentation and expression, its relatively low prevalence in
cardiologic practice, and the complexity of potential patho-
physiologic mechanisms (1,7,36,41,50,59). Nevertheless, it
is possible to identify most high-risk patients by noninvasive
clinical markers (21,22,255), and only a small minority of
those HCM patients who die suddenly (about 3%) are
without any of the currently acknowledged risk markers
(21). The highest risk for SCD has been associated with
the following (Table 2): 1) prior cardiac arrest or spontane-
ously occurring and sustained VT (239); 2) family history
of a premature HCM-related SCD particularly if sud-
den, in a close relative, or if multiple in occurrence (5,7,21);
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3) identification of a high-risk mutant gene (6,19,63,132,245–
247); 4) unexplained syncope, particularly in young patients or
when exertional or recurrent (7,11); 5) nonsustained VT (of
3 beats or more and of at least 120 beats/min) evident on
ambulatory (Holter) ECG recordings (240,242,256–258);
6) abnormal blood pressure response during upright exercise
which is attenuated or hypotensive, indicative of hemody-
namic instability, and of greater predictive value in patients
less than 50 years old or if hypotensive (29,252,253,259);
and 7) extreme LVH with maximum wall thickness of 30
mm or more, particularly in adolescents and young adults
(21,27,28).
Hypertrophic cardiomyopathy patients (particularly those
less than 60 years old) should undergo comprehensive
clinical assessments on an annual basis for risk stratification
and evolution of symptoms, including careful personal and
family history, noninvasive testing with two-dimensional
echocardiography (primarily for assessment of magnitude of
LVH and outflow obstruction), 24- or 48-h ambulatory
(Holter) ECG recording for VT, and blood pressure re-
sponse during maximal upright exercise (treadmill or bicy-
cle). Subsequent risk analysis should be performed period-
ically and when there is a perceived change in clinical status.
Recent attention has focused on the magnitude of LVH
(as assessed by conventional two-dimensional echocardiog-
raphy) as an indicator of risk (27). Two independent groups
have reported a direct association between magnitude of LV
wall thickness and risk of SCD in large HCM populations
(21,22,27). In one study (27), extreme LVH (maximum
thickness of 30 mm or more), present in approximately 10%
of HCM patients, conveyed substantial long-term risk.
Sudden cardiac death was most common in asymptomatic
or mildly symptomatic adolescents or young adults and was
estimated at 20% over 10 years and 40% over 20 years (i.e.,
annual mortality about 2%). There is supporting circum-
stantial evidence from retrospective cross-sectional analyses
that extreme hypertrophy represents a risk factor for pre-
mature SCD because it is observed less commonly in older
than in younger patients (21,22,260); this finding could
reflect either preferential SCD at a young age, structural
remodeling with wall thinning, or both. This relationship of
extreme hypertrophy to age is accentuated with wall thick-
nesses of 35 mm or more, which appear in less than 1% of
patients older than 50 years (260). Other investigators,
however, have maintained that extreme hypertrophy is a
predictor of SCD, only when associated with other risk
factors such as unexplained syncope, family history of
premature SCDs, nonsustained VT on Holter, or an abnor-
mal blood pressure response during exercise (22). At
present, although it is not unequivocably resolved as to
whether extreme hypertrophy as a sole risk factor is suffi-
cient to justify a recommendation for prevention of SCD
with an ICD, serious consideration for such an intervention
should be given to young patients.
The concept that risk of SCD is related to the magnitude
of hypertrophy does not, however, infer that the risk is
necessarily low when LV wall thickness is less than 30 mm,
because other risk markers may be present in a given patient;
indeed, the majority of patients who die suddenly do, in
fact, have wall thicknesses of less than 30 mm (21,22,27,28).
Furthermore, a small number of high-risk pedigrees with
troponin T and I mutations have been reported in whom
SCD was associated with particularly mild forms of LVH,
including a few individuals with normal LV wall thickness
and mass (19,248,261). However, such events appear to be
uncommon within the overall HCM patient spectrum.
Although prognosis is generally not tightly linked to the
pattern and distribution of LVH, the preponderance of
evidence suggests that segmental wall thickening at the low
end of the morphologic spectrum (i.e., less than 20 mm
thickness, regardless of its precise location), generally con-
fers a favorable prognosis in the absence of other major risk
factors (11,27,28). Such localized hypertrophy includes the
nonobstructive form of HCM confined to the most distal
portion of LV (“apical HCM”) (33,40,52).
Disorganized cardiac muscle cell arrangement (4,51,236),
myocardial replacement scarring as a repair process follow-
ing cell death (possibly resulting from ischemia due to
abnormal microvasculature consisting of intramural small
vessel disease or muscle mass-to-coronary flow mismatch)
(129,195,199,200,203) and the expanded interstitial (ma-
trix) collagen compartment (262) probably serve as the
primary arrhythmogenic substrate predisposing some sus-
ceptible patients to re-entrant, life-threatening ventricular
tachyarrhythmias. That extreme degrees of LVH can be
linked to sudden events is perhaps not unexpected, consid-
ering the potential impact of such wall thickening on
myocardial architecture, oxygen demand, coronary vascular
resistance, and capillary density, all of which thereby create
an electrophysiologically unstable substrate. The degree of
hypertrophy does not appear to be directly associated with
the severity of diastolic dysfunction and limiting symptoms
(188,263). Paradoxically, most patients with massive de-
grees of LVH do not experience marked symptomatic
disability (22,27,263), LV outflow obstruction, or left atrial
enlargement.
It is a clinical perception that the premonitory symptom
Table 2. Risk Factors for Sudden Death in HCM*
Major
Possible in Individual
Patients
Cardiac arrest (ventricular fibrillation) Atrial fibrillation
Spontaneous sustained ventricular
tachycardia
Myocardial ischemia
Family history of premature sudden
death
LV outflow obstruction
Unexplained syncope High-risk mutation
LV thickness greater than or equal to
30 mm
Intense (competitive) physical
exertion
Abnormal exercise blood pressure
Nonsustained ventricular tachycardia
(Holter)
*See text for details.
HCM  hypertrophic cardiomyopathy; LV  left ventricular.
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most associated with the likelihood of SCD in HCM is
impaired consciousness (i.e., syncope or near-syncope)
(128,165). However, the sensitivity and specificity of syn-
cope as a predictor of SCD is low, possibly because most
such events in this disease are probably not in fact secondary
to arrhythmias or related to outflow obstruction. Indeed,
there are many potential causes of syncope, some of which
are unrelated to the basic disease state and are often
neurocardiogenic (i.e., vagal, neurally mediated syndromes)
in origin (5,7,11,264). Even when an underlying cause for
impaired consciousness cannot be identified, this symptom-
complex can be compelling in some HCM patients (128),
particularly when it is exertional or recurrent, when it occurs
in the young, or in the context of a single recent syncopal
episode judged to be disease-related. Therefore, syncope
may represent the basis of a defibrillator implant to ensure
preservation of life should a life-threatening arrhythmia
intervene (208).
Available data suggest that LV outflow obstruction (gra-
dient 30 mm Hg or more) can only be regarded as a minor
risk factor for SCD in HCM (29,30,127). The impact of
gradient on SCD risk is not sufficiently strong (positive
predictive value of only 7%) for obstruction to merit a role
as the sole (or predominant) deciding clinical parameter and
the primary basis for decisions to intervene prophylactically
with an ICD (127).
Identification of HCM in young children is exceedingly
uncommon and often creates a specific clinical dilemma
because such an initial diagnosis occurring so early in life
(frequently fortuitously) raises uncertainty regarding future
risk over particularly long time periods. One report suggests
that short-tunneled (bridged) intramyocardial segments of
left anterior descending coronary artery independently con-
vey increased risk for cardiac arrest, probably mediated by
myocardial ischemia (238). However, potential biases in
patient selection, the frequency of coronary arterial bridging
in surviving adults and those who have died of noncardiac
causes, and the need for routine invasive coronary arteriog-
raphy in order to identify this abnormality prospectively
seem to mitigate the potential power of coronary bridging as
a risk factor for SCD.
It has been proposed, based on genotype-phenotype
correlations, that the genetic defects responsible for HCM
could represent the primary determinant and stratifying
marker of prognosis and for SCD and heart failure risk,
with specific mutations conveying either favorable or ad-
verse prognosis (i.e., high- and low-risk mutations)
(6,19,132,138,247,265,266). For example, it has been sug-
gested that some cardiac beta-myosin heavy chain muta-
tions (such as Arg403Gln and Arg719Gln) and some
troponin-T mutations are associated with higher incidence
of premature death, decreased life expectancy, and early
onset disease manifestations, while other HCM genes such
as cardiac myosin-binding protein C (particularly InsG791)
or alpha-tropomyosin (Asp175Asn) convey a more favor-
able prognosis (63). However, routine clinical testing for
specific mutations believed to be high (or low) risk has been
shown to have low yield (265,266). Therefore, it is prema-
ture to draw definitive conclusions regarding gene-specific
clinical outcomes based solely on the presence of a particular
mutation, by virtue of extrapolation from available
epidemiologic-genetic data which are formulated from rel-
atively small numbers of genotyped families largely skewed
toward high-risk status (6). Consequently, it is becoming
increasingly evident that the presence or absence of a
particular mutation does not by itself represent sufficient
data to convey clear prognostic implications and that HCM
mutations may not possess distinctive clinical signatures.
The particular prognosis attached to adult carriers with a
mutant HCM gene but without LVH and clinical expres-
sion of HCM (54,245), or those individuals who develop
hypertrophy de novo in adulthood (6,17,64,65,146), is un-
certain; however, at this early juncture, this subgroup would
not appear to be associated with an adverse prognosis (Fig.
1). An exception to this tenet may be the small number of
SCDs in young people with little or no LVH reported in a
very few families with troponin-T mutations (19,245,
247,248).
There is no convincing evidence that invasive markers
such as those defined with laboratory electrophysiologic
testing (i.e., programmed ventricular stimulation) (264,267)
have an important routine role in identifying those HCM
patients who have an unstable electrical substrate and are at
high-risk for SCD due to life-threatening arrhythmias.
Similar to the experience in CAD and dilated cardiomyop-
athy, polymorphic VT and ventricular fibrillation (VF)
(which are the most commonly provoked arrhythmias) are
generally regarded as nonspecific electrophysiologic testing
responses to multiple ventricular extra-stimuli (5,11), and
these specialized laboratory studies are highly dependant on
the level of aggression of the protocol (267). For example,
stimulation with three ventricular premature depolarizations
rarely triggers monomorphic VT in HCM (in contrast to
CAD), but frequently induces polymorphic VT or VF, even
in some patients at low risk for SCD.
It is now the predominant view that the risk stratification
strategies involving laboratory induction of such ventricular
arrhythmias are neither desirable in HCM patients on a
routine basis nor, per se, justify aggressive intervention
(5,7,11). Electrophysiologic studies with or without pro-
grammed ventricular stimulation may, however, have some
value in selected patients such as those with otherwise
unexplained syncope.
Most of the clinical markers of SCD risk in HCM are
limited by relatively low positive predictive values due in
part to relatively low event rates (11,21,27,28,30,242).
However, the high negative predictive values (at least 90%)
of these markers suggest that the absence of risk factors and
certain other clinical features can be used to develop a profile
of patients having a low likelihood of SCD or other adverse
events (11). Adult patients can probably be considered low
risk if they demonstrate: 1) no or only mild symptoms of
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chest pain or exertional dyspnea (NYHA functional classes
I and II); 2) absence of family history of premature death
from HCM; 3) absence of syncope judged to be HCM-
related; 4) absence of nonsustained VT during ambulatory
(Holter) ECG; 5) outflow tract gradient at rest of less than
30 mm Hg); 6) normal or relatively mild increase in left
atrial size (less than 45 mm); 7) normal blood pressure
response to upright exercise; and 8) mild LVH (wall
thickness less than 20 mm).
Patients with an apparently favorable prognosis in the
absence of risk factors constitute an important proportion of
the overall HCM population. Most such patients probably
will not require aggressive major medical treatment and
generally deserve a large measure of reassurance regarding
their prognoses. Little or no restriction is necessary with
regard to recreational activities and employment, although
exclusion from intense competitive sports is advised.
Prevention. Efforts at the prevention of SCD have histor-
ically targeted only the minority of patients with HCM in
whom SCD risk was unacceptably high. Historically, treat-
ment strategies to prophylactically reduce the risk for SCD
or delay progression of congestive symptoms have been
predicated on the administration of drugs such as beta-
adrenergic blockers, verapamil, and type I-A antiarrhythmic
agents (i.e., quinidine, procainamide) to those patients
perceived to be at high risk. However, there is no evidence
that this practice of prophylactically administering such
drugs empirically to asymptomatic HCM patients to miti-
gate the risk for SCD is efficacious, and this strategy now
seems out-dated with the current availability of measures
that more effectively prevent SCD, such as the ICD. In
addition, low dose (less than 300 mg) amiodarone has been
associated with improved survival in HCM (243,257), but
this agent requires careful monitoring and may not be
tolerated due to its potential toxicity over the long risk
periods incurred by young patients.
When risk level for SCD is judged by contemporary
criteria to be unacceptably high and deserving of interven-
tion, the ICD is the most effective and reliable treatment
option available, harboring the potential for absolute pro-
tection and altering the natural history of this disease in
some patients (208,209,237,268) (Fig. 1). In one multi-
center retrospective study, ICDs appropriately sensed and
automatically aborted potentially lethal ventricular tachyar-
rhythmias by restoring sinus rhythm in almost 25% of a
high-risk cohort, followed for a relatively brief period of 3
years (208). Appropriate device interventions occurred at a
rate of 11% per year for secondary prevention (the implant
following cardiac arrest or spontaneous and sustained VT)
and at 5% per year for primary prevention (implant based
solely on noninvasive risk factors), usually in patients with
no or only mild prior symptoms. There was only a 4 to 1
excess of ICDs implanted to lives saved. Patients receiving
appropriate defibrillation shocks were generally young
(mean age 40 years). Implantable cardioverter defibrillators
often remained dormant for prolonged periods before dis-
charging (up to 9 years), emphasizing the unpredictable
timing of SCD events in this disease, the potentially long
risk period, and the requirement for extended follow-up
duration to assess survival in HCM studies (26,208). There-
fore, while the decision to implant a defibrillator for primary
prevention cannot reasonably be deferred beyond the time
when high-risk status is first judged to be present, it may
precede considerably the time at which the device ultimately
discharges. There is an ongoing multicenter international
study of HCM patients with ICDs (208) for the purpose of
obtaining data on interventional devices in a much larger
population over longer periods of time.
The ICD is strongly warranted for secondary prevention
of SCD in those patients with prior cardiac arrest or
sustained and spontaneously occurring VT (7,208). The
presence of multiple clinical risk factors conveys increasing
risk for SCD of sufficient magnitude to justify aggressive
prophylactic treatment with an ICD for primary prevention
of SCD (208,268). Strong consideration should be afforded
for a prophylactic ICD in the presence of one risk factor
regarded as major in that patient (e.g., a family history of
SCD in close relatives) (7,27,268).
Because the positive predictive value of any single risk
factor is low, such management decisions must often be
based on individual judgment for the particular patient, by
taking into account the overall clinical profile including age,
the strength of the risk factor identified, the level of risk
acceptable to the patient and family, and the potential
complications largely related to the lead systems and to
inappropriate device discharges. It is also worth noting that
physician and patient attitudes toward ICDs (and the access
to such devices within the respective health care system) can
vary considerably among countries and cultures and thereby
have an important impact on clinical decision-making and
the threshold for implant in HCM (269). The ACC/AHA/
NASPE 2002 guidelines have designated the ICD for
primary prevention of SCD as a class IIb indication and for
secondary prevention (after cardiac arrest) as a class I
indication (225).
There is, at present, an understandable reluctance on the
part of pediatric cardiologists to implant such devices
chronically in children (particularly for primary prevention)
considering the necessary, ongoing commitment required
for maintenance and the likelihood that lead or other
(ICD-related) complications will occur over very long time
periods. However, while adolescence may represent a psy-
chologically difficult age to be encumbered by an ICD, it
should also be emphasized that this is coincidently the
period of life consistently showing the greatest predilection
for SCD in HCM (7,21–23,25–28,208). One alternative
but empiric strategy proposed for some very young high-risk
children is the administration of amiodarone as a bridge to
later ICD placement after sufficient growth and maturation
has occurred. Some investigators also regard the end-stage
phase of HCM as a risk factor for SCD, justifying implan-
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tation of a cardioverter-defibrillator during the waiting
period prior to the availability of a heart for transplant.
Athlete recommendations. In accord with the recommen-
dations of the Expert Consensus Panel of the 26th Bethesda
Conference (241), young patients with HCM should be
restricted from intense competitive sports to reduce the risk
for SCD that may be associated with such extreme lifestyle.
A linkage has been established between SCD and intense
exertion in trained athletes with underlying cardiovascular
disease (including HCM) and SCD (25,270).
There is indirect and circumstantial evidence that the
removal of young athletes from the competitive arena
reduces risk for SCD (241,271). Not all trained athletes
with HCM die suddenly during their competitive phase of
life, only some HCM-related SCDs are associated with
intense physical activity (25,26), and precision in the strat-
ification of risk for athletes with HCM is particularly
difficult given the extreme environmental conditions to
which they are often exposed (associated with alterations in
blood volume hydration and with electrolytes). Neverthe-
less, the consensus of the general medical community
prudently supports avoiding exposure to most competitive
sports for young athletes with HCM to reduce SCD risk,
and therefore withdrawal from the athletic arena can be
regarded as a treatment modality in this disease (241,271).
However, stringent lifestyle or employment modifications
for other HCM patients (who are not participants in
organized athletics) do not seem justified or practical,
although intense physical activity involving burst exertion
(e.g., sprinting) or systematic isometric exercise (e.g., heavy
lifting) should be discouraged. Although data are scarce,
there is presently no evidence to suggest that genetically
affected but phenotypically normal family members are
generally at increased risk for SCD. Therefore, there is little
basis for subjecting such individuals to the same activity
restrictions as many other HCM patients, or excluding
them from competitive athletics in the absence of cardiac
symptoms, family history of SCD, or a mutant gene
regarded as malignant. However, periodic (probably annual)
noninvasive clinical evaluation directed toward risk assess-
ment is warranted in this subset of patients.
ATRIAL FIBRILLATION
Atrial fibrillation is the most common sustained arrhythmia
in HCM and usually justifies aggressive therapeutic strate-
gies (30,38,161–163,249) (Fig. 1). Paroxysmal episodes or
chronic AF ultimately occur in 20% to 25% of HCM
patients (30,163,249), linked to left atrial enlargement and
an increasing incidence with age (163). Furthermore, it is
possible that subclinical AF (i.e., identified only by Holter
recording) may be even more common. Clinical cohort
studies show that AF is reasonably well tolerated by about
one-third of patients and is not an independent determinant
of sudden unexpected death (163); however, it is possible
that in certain susceptible patients, AF may trigger life-
threatening ventricular arrhythmias (244,254). Neverthe-
less, AF is independently associated with heart failure-
related death, occurrence of fatal and nonfatal stroke, as well
as long-term disease progression with heart failure symp-
toms (38,161,163); transient episodes occur in about 30% of
patients immediately following septal myectomy, often in
patients with a prior history of AF (202). Risk for compli-
cations of AF is enhanced when the arrhythmia becomes
chronic, onset is before 50 years of age, and outflow
obstruction is present (163).
Paroxysmal episodes of AF may also be responsible for
acute clinical deterioration, with syncope or heart failure
resulting from reduced diastolic filling and cardiac out-
put—as a consequence of increased ventricular rate and with
loss of atrial contraction (and its contribution to ventricular
filling) in a hypertrophied LV with pre-existing impaired
relaxation and compliance (161–163). Atrial fibrillation in
HCM should be managed generally in accordance with the
ACC/AHA guidelines (272). In particular, electrical or
pharmacologic cardioversion are indicated in those patients
presenting within 48 h of onset, assuming that the presence
of atrial thrombi can be excluded with a reasonable degree of
certainty. Although comparative data regarding the efficacy
of antiarrhythmic drugs are not available for HCM patients,
amiodarone is generally regarded as the most effective
antiarrhythmic agent for preventing recurrences of AF,
based largely on extrapolation from its use in other heart
diseases (272,273).
A generally aggressive strategy for maintaining sinus
rhythm is warranted in HCM because of the association of
AF with progressive heart failure and mortality, as well as
stroke (38). In chronic AF, beta-blockers, verapamil (and
digoxin) have proved effective in controlling heart rate,
although A-V node ablation and permanent ventricular
pacing may occasionally be necessary in selected patients.
Anticoagulant therapy (with warfarin) is indicated in pa-
tients with either paroxysmal or chronic AF (7,11,38,163).
Because even one or two episodes of paroxysmal AF have
been associated with increased risk for systemic thrombo-
embolization in HCM, the threshold for initiation of
anticoagulant therapy should be low and can include pa-
tients after the initial AF paroxysm (7,38,163). Since
warfarin has proved superior to aspirin in other cardiac
conditions associated with AF, it is the recommended
anticoagulant agent in HCM patients judged to be at risk
for thromboembolism. While anticoagulation reduces the
risk of thromboembolic events in patients with AF and
HCM, it is also recognized that anticoagulation does not
completely abolish the risk of stroke (38,163). Such clinical
decisions should be tailored to the individual patient after
considering the risk for hemorrhagic complications, lifestyle
modifications, and expectations for compliance.
The most appropriate management for patients with
asymptomatic nonsustained supraventricular tachycardia
(detected only on ambulatory [Holter] ECG or exercise-
testing), and associated with left atrial enlargement is
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presently unresolved. Also, at present, there is little experi-
ence specifically in HCM patients with emerging and novel
alternative treatment strategies for AF such as pulmonary
vein radio-frequency ablation, the surgical MAZE proce-
dure, or implantable atrial defibrillators to warrant definitive
recommendations at this time.
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